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Abstract: 
Background:  Pnuemonia is a leading cause of morbidity and mortality worldwide and 
children diagnosed with asthma have been shown to be at greatly increased risk of recurrent 
Community-Acquired Pneumonia (CAP).  CAP in asthmatic children can incur nearly double the 
healthcare costs and lead to poorer outcomes during the course of the pneumonia infection.   
Objective: This study seeks to determine if sputum (SP) samples may be used in the 
pediatric population to better understand the microbiome environment during severe pneumonia 
in place or in conjunction with the more commonly used nasopharyngeal (NP) samples.  
Additionally, this study seeks to identify features of the microbiome associated with pneumonia 
severity in asthmatic children. 
Methods: Sputum and nasopharyngeal/oropharyngeal (NP/OP) samples were collected 
from asthmatic children diagnosed with asthma upon admission to a hospital.  Bacterial cultures 
for known CAP pathogens using sputum samples, and PCR detection for viral pneumonia 
pathogens on the NP/OP samples were performed.  To study the microbiome, 16s rRNA analysis 
of sputum and nasopharyngeal samples was performed and analysis conducted using a variety of 
single and community-based analyses.  Outcomes of interest were LOS > 4 days and admission 
to the ICU.      
Results: High relative abundance of CAP pathogens, including Moraxella and 
Haemophilus, were associated with poorer CAP outcomes in both age groups for both ICU 
admission and longer LOS.  Similarly, a positive sputum culture result for Staphylococcus 
aureus was found to be significantly associated with more severe pneumonia.  Bacteroidetes was 
associated with shorter LOS and Rothia association with longer LOS in several of the analyses.  
Both conclusions are consistent with previous characterizations of the bacteria in the onset of 
pneumonia and asthma.  Moraxella was consistently associated with longer LOS and increased 
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risk of ICU admission, consistent with its characterization as a minor CAP pathogen, but was 
protective against longer LOS in the younger age group.  
Conclusions:  First, our study demonstrates that sputum samples may be used in a 
pediatric population.  Our findings demonstrate that many of the microbiome features previously 
identified as being predictive of, or associated with, CAP, also serve to predict severe pneumonia 
outcomes in this pediatric population, including longer Length of Stay (LOS) and Intensive Care 
Unit (ICU) admission.  However, certain inconsistencies in the trends in our data highlight the 
need to perform microbiome analyses using many different approaches to fully understand the 
complex relationships between the diverse commensal and pathogenic bacteria that comprise the 
microbiome. 
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Introduction: 
Pneumonia is among the three leading causes of admission for pediatric patients and remains a 
major cause of morbidity and mortality worldwide in pediatric populations (Parikh, 2014; Vila-
Corcoles, 2012).  Pneumonia is most commonly found in children under four years of age and 
adults sixty-five or older (Myles, 2009).  From within the community, this so-named 
Community-Acquired Pneumonia (CAP) has been primarily linked to four bacterium when of 
bacterial etiology: Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus 
and Moraxella catarrhalis (Cevey-Macherel, 2009).  Recently, the widespread use of the 13-
valent conjugate pneumococcal vaccine targeting S. pnuemoniae has reduced the prevalence of 
pneumonia in the population.  Yet there remains a significant burden of pneumonia, as well as 
possible concerns regarding continued efficacy of the vaccine due to increasing burden of non-
vaccine S. pneumoniae serotypes (Maldonado, 2014).  Within the U.S. population, asthmatics 
represent a community who are at increased risk for developing pneumonia (Obert, 2012; Talbot, 
2005; Maldonado, 2014; Patria, 2013).  Asthma exacerbations are associated with increased 
health care costs and poorer outcomes among patients, and these exacerbations can often be 
caused by infections with CAP pathogens (Ivanova, 2012).   
This relationship between asthma and pneumonia has been supported by a broad range of 
biological data demonstrating an increased susceptibility towards infection, however the 
mechanism of this increased susceptibility is not yet clear.  In the pediatric population, asthmatic 
patients have been shown to have a deficient cellular and humoral immune response to 
Mycoplasma pneumoniae infection compared with non-asthmatic controls (Atkinson, 2009).  
Some studies have looked at a genetically-determined immune response present in asthmatics, 
mediating the susceptibility to pneumonia while others have looked at structural changes in the 
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respiratory tract (McKeever, 2013).  However, asthma diagnoses have also been associated with 
the presence of pneumonia pathogens such as Human Rhinovirus (HRV), Chlamydophila 
pneumoniae and Mycoplasma pneumoniae (Lu, 2014; Specjalski, 2011), as well as increased 
diversity within the bronchial microbiota, mainly attributed to the presence of pathogenic 
bacteria (Hilty, 2010; Huang, 2013).  Pathogenic proteobacteria, particularly Haemophilus spp., 
were far more common in asthmatic patients, both adults and children, while Bacteroidetes, 
especially Prevotella spp., were less frequent in the asthmatic population and possibly played a 
protective role against invasion (Hilty, 2010).  Disturbed microbiota have often been implicated 
as a risk factor for susceptibility toward invading pathogens and the development of pneumonia.  
In this study we seek to investigate the relationship between the microbiome and asthma by 
looking at the severity of disease within pneumonia patients.  Most studies pneumonia have 
focused on the relationship between the microbiome and the risk of developing pneumonia 
(Boutin, 2013).  To the best of our knowledge, no study has yet looked at the relationship 
between the microbiome and the severity of pneumonia within the asthmatic population. 
Previous culture based analyses have also revealed specific etiologies associated with pneumonia 
and the onset of pneumonia.  Within pediatric patients, S. pneumoniae (46) and rhinovirus (29) 
were found to be the most common microbes detected in CAP (Lahti, 2009).  A prospective 
cohort study found that neonatal airway colonization by S. pneumoniae, H. influenzae or M. 
catarrhalis led to increased risk of pneumonia and bronchiolitis in the first three years of life, 
independent of asthma diagnosis (Vissing, 2013).  When nasopharyngeal samples were used to 
diagnose the etiology of CAP in pediatric patients diagnosed with acute asthma, 35% of the 
pediatric patients were diagnosed with viral pneumonia (Isaacs, 1989).  However, in the same 
study radiographic tests and clinical criteria were unable to distinguish between viral and 
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bacterial pneumonia, highlighting the need for other tests in the clinical diagnosis of the 
pneumonia pathogen. 
Additionally, there are questions surrounding the validity of various diagnostic tests used to 
detect and diagnose pneumonia.  Nasopharyngeal samples are often used in diagnosis, but may 
be susceptible to underdiagnosis of S. aureus and overdetection of asymptomatic pathogenic 
bacteria that are capable of colonizing the nasopharynx (Isaacs, 1989; Nolte, 2008; Kumar, 
2008).  Induced sputum samples have previously been used to test for the presence or absence of 
CAP pathogens in pneumonia patients (Specjalski, 2011).  Sputum samples have been proposed 
as an alternative strategy to enhance detection of some pathogens.  Sputum samples were 
successfully used in a recent study of pediatric populations diagnosed with CAP and were used 
to microbiologically identify the causative agent of the pneumonia in 90% of cases (Lahti, 2009).  
Moreover, one-quarter of all of the identified bacterial pathogens were only detected in the 
sputum, not in the nasopharyngeal samples (Lahti, 2009).  In this study we seek to assess the 
relative value of the sputum and the nasopharyngeal samples in predicting pneumonia disease 
severity and their value as surrogates for evaluating the lung microbiome.  
Methods: 
These data and samples were all from the recently conducted Centers for Disease Control (CDC) 
study on the Etiology of Pneumonia in the Community (EPIC) (Jain, 2015).  The EPIC study was 
a prospective, multi-site, population-based active surveillance study to determine the incidence 
and etiology of CAP in children (Jain, 2015).  Subjects under 18 years of age were identified and 
eligible for entry into the study when seeking medical care for respiratory illness to Le Bonheur 
Children’s Hospital (LBCH) or the LBCH catchment area in Memphis Tennessee.  Patients were 
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examined for clinical evidence of pneumonia, and the final study sample was limited to only 
those patients with an abnormal chest X-ray confirming the presence of pneumonia.  Upon 
enrollment in the study, patients completed a full medical history questionnaire, and provided 
samples of whole blood, induced sputum sample (SP), blood culture, nasopharyngeal swab (NP), 
oropharyngeal swab (OP) and serum samples at admission (acute).  The following tests were 
performed on the specimens: culture of blood and NP/OP secretions for bacteria, real-time 
polymerase chain reaction (PCR) for influenza viruses A and B, respiratory syncytial virus 
(RSV), human metapneumovirus (hMPV), parainfluenza virus (PIV) 1, 2 and 3, coronaviruses 
229E, OC43, NL63 and HKU1, adenovirus, rhinoviruses, S. pneumoniae, Legionella 
pneumophila, M. pneumoniae, and Chlamydia pneumoniae (NP/OP secretions), PCR for S. 
pneumoniae and Group A Streptococcus (whole blood) , Enzyme Immunoassay (EIA) (Remel) 
for M. pneumoniae, Microimmunofluorescence (MIF) for C. pneumoniae (serum),  Enzyme-
Linked Immunosorbent Assay (ELISA) for influenza viruses A and B, RSV, hMPV, and PIV 1, 
2, 3, PCR for S. aureus using whole blood, and the culture of induced sputum for bacteria in 
children.  The final sample size was 208 pediatric patients when the sample was limited only to 
children who had both their NP/OP and SP sample successfully amplify for the 16S ribosomal 
analysis, as well as having X-ray confirmed pneumonia, and a confirmed history of asthma.   
16s RNA Analysis: 
The microbiome samples were analyzed through the hypervariable regions V4 of the 16S 
ribosomal RNA using bar-coded 16sRNA primers as previously described (Caporaso, 2012).  
Initial cleaning, binning, and processing of sequence reads were done using Btrim (Kong, 2011).  
Sequences were scanned for linkers and primers while allowing for two errors, and primer 
sequences were removed from each sequence read.  Reads missing the 5’-end primer were 
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removed from the data set.  Bar codes were identified, allowing for one error, and trimmed after 
sequence reads were binned into separate FASTA files.   
Sequences were aligned using Infernal 1.1 available from the Ribosomal Database Project (RDP) 
(Cole, 2009).  Strict alignment criteria were set to minimize the number of chimeras: all 
sequences had to align to at least 200 bp of the 16S rRNA gene, and any sequence aligning 
outside of the 27 or the 338 position of the 16s rRNA gene was discarded.  Taxonomic 
identification of samples was achieved using the RDP Bayesian classifier tool at 90% confidence 
from the RDP pipeline on the RDP database project.  Those bacteria that failed to classify to an 
order were labeled as “unclassified”.  Following classification, sequence reads were then 
clustered (RDP pipeline) into Operational Taxonomic Units (OTU’s), defined in an iterative 
process beginning first with genus level identification, and then moving up to the next taxonomic 
level when the lower level grouping was not available.  Individual samples were assessed for 
measures of microbiome diversity, calculating the evenness and Shannon Index (RDP pipeline).   
Statistical Analysis: 
The population was stratified into older than and younger than five years of age for all analyses 
due to differences between the populations and potential complications with differences in 
diagnostic practices for asthma in these age groups (asthma is not considered to be an 
appropriate diagnosis prior to five years of age).  Disease severity was measured through hospital 
Length of Stay (LOS) as a dichotomous categorical variable, categorizing those with LOS >4 
days as having the outcome of interest.  This cutoff was chosen because the top quartile of LOS 
(q4 >4.29 days) closely correlated with those having LOS greater than four days (26.6% of study 
population had LOS >4 days).  Intensive Care Unit (ICU) admission was also used in a subgroup 
analysis as a dichotomous variable in patients older than five years of age; the analysis was only 
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performed in the older age group as the frequency of ICU visitation was not high enough in the 
lower age group to provide adequate power to the analysis.  Unadjusted associations for outcome 
variables LOS and ICU admission, as well as potential confounders, presence of cultured 
pathogens, and diversity measures were calculated using a chi–square test or t-test as 
appropriate.  
For all subsequent analyses, a cutoff of 0.6% mean relative abundance within either the NP/OP 
or the SP samples was used for each taxa.  This left 26 taxa for subsequent analyses and all 
remaining taxa or unclassified sequences were combined into the category “meta_other”.  We 
used several measures of microbial community structure.  1) Principal component analysis 
(PCA) was performed in SAS 9.4 (SAS Institute, Cary NC) on both the SP and NP/OP 16S RNA 
samples to determine associated groups of bacteria, and the resulting factor scores being used in 
the logistic regression.  2) Linear Discriminant Analysis (LDA) was performed using LefSE to 
determine significantly differentiated taxa between those with and without severe disease, as 
well as between the NP/OP and SP samples within each category (Segata, 2011).  Each 
participant was then assigned as being either in the lower three or top quartile with respect to the 
relative abundance of each of the significantly enriched taxa.  These dichotomous categorical 
variables for significantly enriched taxa were then input into a logistic regression model.  3) 
Lastly, a community typing analysis using SimClust (Walesiak, 2014) in R (R Core Team, 2014) 
was used to cluster patients into groups with similar microbiome profiles.  RandomForest (Liaw, 
2012) in R was then used to determine the significantly discriminant features of the community 
types.  
All logistic regressions were stratified by age and performed separately by outcome variable in 
SAS 9.4, resulting in three models, unless stated otherwise: (i) LOS outcome in the < 5 age 
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group, (ii) LOS outcome in the ≥ 5 age group and lastly (iii) ICU outcome in the ≥ 5 age group.  
The first logistic regression models were created using the diversity measures for evenness and 
the Shannon Index.  Community types were used as a categorical variable in logistic regression 
models.  Additionally, heat maps of the community types were created in R by determining the 
proportion of patients of each community type in the fourth quartile for relative abundance of 
each taxa.  Potential confounders included sex, race, education, type of facility the patient was 
admitted from, presence of co-morbidities, prior antibiotic use, oral steroid use, inhaled steroid 
use, and vaccination history for seasonal influenza, pneumococcal-7 or 13 conjugate and H. 
influenza B.  Pathogens included S. pneumoniae, S. aureus, M. catarrhalis, H. influenzae, M. 
pneumoniae, Rhinovirus, RSV, adenovirus, coronavirus, H. parainfluenzae, and hMPV.  
Results and Discussion: 
1. Study Population 
All of the analyses were performed upon an age-stratified population, where children were 
grouped into the younger category less than five years of age, and the older age group of children 
from five to less than eighteen years of age.  This cutoff was selected due to the difficulties and 
controversy in diagnosing asthma in those under five years of age (Mayo Clinic Staff, 2015).  
Official guidelines dictate that asthma cannot be properly diagnosed in children under the age of 
five as many of these children will eventually grow out of the asthma as they become older.  This 
has several implications for this study, namely that the population of children diagnosed with 
asthma under the age of five may well be a different population than those who maintain their 
asthma diagnosis past the age of five.  Thus, we elected to stratify the analysis by age for all of 
the analyses in this study.  
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Demographic, vaccination and clinical characteristics of the stratified study population are 
described in Table 1 by LOS and Table 2 by ICU admission.  Within both age groups, there were 
slightly more males than females, with 44.4% and 42.9% of the population being female in the 
younger and older age groups respectively.  Most of the population was admitted into the 
hospital directly from home, 82.5% and 63.6% coming from home in the younger and older age 
group respectively.  Although 7.1% and 10.4% came from outpatient clinics in the younger and 
older age groups respectively; and 9.5% of the younger and 26.0% of the older age group came 
from another hospital.  The majority of the study’s population was black, with 82.5% and 88.3% 
of the population identifying as black in the younger and older age groups respectively, with the 
rest of the population roughly evenly split between white and other races.  Race does appear to 
be a significant unadjusted association with LOS in the younger age group (p-value = 0.014).  
There was no significant unadjusted association found between LOS and ICU admission with 
education, presence of co-morbidities, prior antibiotic history, oral steroid use, inhaled steroid 
use, and H. Influenzae vaccination.  Nearly all of the study’s population had previously received 
the Pneumococcal-7 or 13 conjugate vaccine, though coverage was not as high among the older 
age group (81.8%), with the pneumococcal vaccine appearing to have a significant unadjusted 
association with LOS in the older age group.    
Tables 3 and 4 present the unadjusted associations between the different culture results for the 
CAP bacterial pathogens, while Tables 5 and 6 presents the same for the PCR tests for the viral 
pathogens and bacteria.  There did not appear to be any association between a positive culture for 
S. pneumoniae, M. catarrhalis, H. influenzae, and M. pneumoniae and either of the disease 
outcomes in the analysis.  However, a positive S. aureus culture did appear to have a significant 
association with increased LOS in the younger age group (p<0.001).  Similarly, there was no 
  
9 
significant association found between a positive PCR viral test for rhinovirus, RSV, adenovirus, 
coronavirus, PIV, or hMPV, and either of the pneumonia severity markers, LOS or ICU 
admission.  
2. Differences between the NP/OP and SP samples within the population.   
Relationship between diversity measures and disease severity within NP/OP and SP samples: 
There were significant differences found between the NP/OP and SP samples with respect to the 
diversity indices.  The SP samples were consistently less diverse with respect to both evenness 
and the Shannon Index in the total study population (Evenness: p=0.031; Shannon: p <0.001) as 
well the younger age group (Evenness: p < 0.001; Shannon: p <0.001) (Table 7).  However, 
within the older age group, the SP samples were actually found to be significantly more diverse 
than the NP/OP samples with respect to the samples’ evenness (p=0.018), though there was no 
significant difference found in the Shannon Index.  Thus the SP sample does appear to be 
capturing a different microbiota than the NP/OP samples.  However, despite the differences 
between the two sample types, neither of the measures of microbiota diversity tested were found 
to be significantly associated with either ICU admission or LOS in the adjusted analyses within 
either age group.  
Top taxa from the 16s rRNA data: 
Table 8 shows the top 26 taxa that had the highest mean relative abundance from either the SP or 
NP/OP samples.  Streptococcus was the most prevalent taxa in both samples comprising roughly 
19 of the reads in both the NP/OP and SP samples.  Genera previously implicated to play a role 
or have increased abundance in the presence of CAP, including Prevotella, Veillonella, Rothia, 
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Neisseria, Fusobacterium, Haemophilus, Moraxella and Actinomyces, were all found to rank 
highly in relative abundance here as well (Chen, 2013; Garzoni, 2013; Sakwinska, 2014).   
In an LDA analysis comparing the taxa between the NP/OP and the SP samples, genera 
Atopobium, and family Actinomycetaceae were significantly enriched in the NP/OP samples of 
both the older and the younger age groups, while phylum Bacteroidetes was significantly 
enriched in the SP samples of both the older and the younger age group (Figure 1).  Within the 
younger age group, 7 taxa, along with the grouped rare taxa, were significantly enriched in the 
NP/OP samples, and 3 taxa were significantly enriched within the SP samples.  The older age 
group had 4 taxa with significantly higher relative abundance in the NP/OP samples, and eight 
significantly enriched in the SP samples.   
3. Associations between individual taxa in SP samples and pneumonia disease severity.   
Within the younger age group, Corynebacterium and Actinomyces were significantly enriched in 
those children who had LOS shorter than four days (Figure 2a).  In the adjusted analysis, patients 
in the top quartile for relative abundance of Corynebacterium and Actinomyces were found to be 
associated with shorter LOS after pneumonia diagnosis (OR= 0.30: 0.10-0.93, p=0.0372; OR= 
0.30: 0.10-0.93, p=0.0372 respectively).  Positive S. aureus culture was also found to be a 
significant covariate in the younger age group and with a positive culture being associated with 
LOS longer than four days (OR=4.96: 1.83-13.42, p=0.002).  In the older age group, 
Streptococcus, Atopobium, Moraxella, family Actinomycetaceae, Leptotrichia and family 
Veillonellaceae were all significantly enriched in the samples of those children who had shorter 
LOS (Figure 2b).  However, in the adjusted analysis, none of the taxa were significantly 
associated with longer LOS.  Within the older age group, the high relative abundance of 
Moraxella was found to be significantly associated a risk of ICU admission (OR=4.97: 1.10-
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22.50, p=0.037).  In the final adjusted model for ICU admission in the older age group, recent flu 
vaccination was found to be a significant covariate, with recent flu vaccination being positively 
correlated with ICU admission (OR=4.83: 1.01-23.13, p=0.049).  This was unexpected, but may 
be due to those receiving the vaccination being more likely to have severe underlying conditions; 
they may have been sicker to begin with.     
4. Relationships between correlated taxa and pneumonia severity.   
Within the microbiota, members of the commensal flora may co-aggregate or be more likely to 
co-colonize based on similar nutritional requirements or the member’s use of various waste 
products and secondary metabolites (Rickard et al., 2003; Willing et al., 2011).  Thus, PCA was 
used to identify groups of taxa (factors) that correlated with each other within each of the 
stratified samples.  The SP samples in the younger age group produced four independent factors 
(Table 9), while PCA for the SP samples in the older age group produced five independent 
factors (Table 10).   
Stratified analysis in patients younger than five: 
(i) Atopobium, Veillonella, Actinomycetaceae, and Actinomyces.  As a group, the relative 
abundance of these Factor 1 taxa, genera Atopobium, Veillonella, Actinomyces and the family 
Actinomycetaceae, did not differ significantly by LOS outcome. 
(ii) Leptotrichia, Capnocytophaga, Neisseria, Lactobacillales. Betaproteobacteria, Moraxella, 
and rare taxa.  The PCA Factor 2 taxa include genera Leptotrichia, Capnocytophaga, Neisseria, 
Moraxella, suborder Lactobacillales, class Betaproteobacteria, and the rare taxa.  However, the 
relative abundance of these taxa as a group was not found to significantly differ with LOS 
outcome.   
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(iii) Mycoplasma, Veillonellaceae, Leptotrichiaceae and Bacteroidetes.  Genera Mycoplasma, 
families Veillonellaceae, Leptotrichiaceae and phylum Bacteroidetes are all positively correlated 
with PCA factor 3.  As a group, the taxa in factor 3 are significantly associated with shorter LOS 
and appear to be protective (OR= 0.49: 0.26-0.91, p=0.023).   
(iv) Moraxella, Corynebacterium, Dolosigranulum, Fusobacterium, Leptotrichiaceae and 
Bacteroidales.  The taxa in PCA factor 4, comprised of genera Moraxella, Corynebacterium, 
Dolosigranulum, Fusobacterium, family Leptotrichiaceae and suborder Bacteroidales, appears 
to be protective and is significantly associated with shorter LOS (OR=0.536: 0.30-0.96, 
p=0.035).  Genus Fusobacterium, family Leptotrichiaceae and suborder Bacteroidales are 
negatively correlated with the factor 4, and a decrease in their relative abundance appears to be 
protective against longer hospital stays.  In contrast, the genera Moraxella, Corynebacterium and 
Dolosigranulum are positively correlated with factor 4 in the younger children and an increase in 
their relative abundance appears to be protective against longer LOS.    
Stratified analysis in patients older than five: 
(i) Veillonella, Atopobium, Actinomyces, Prevotella, Neisseria, and Pasteurellaceae.   The 
genera Veillonella, Atopobium, Actinomyces, Prevotella, Neisseria, and family Pasteurellaceae 
comprise PCA factor 1 in the older children (Table 10).  Taken as a group, the relative 
abundance of Factor 1 taxa does not significantly differ by LOS or ICU admission. 
(ii) Dolosigranulum, Corynebacterium, and Rothia. PCA factor 2 is comprised of 
Dolsigranulum, Corynebacterium and Rothia, all of which are positively associated with the 
factor.  These taxa appear to be, as a group, associated with increased odds of longer LOS in the 
older age group (OR=3.18: 1.15-8.85, p=0.026).  In the final model, a 7-conjugate pneumonia 
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vaccine was also found to be a significant protective covariate, with reduced odds of longer LOS 
(OR=0.09: 0.02-0.36, p=<0.001). 
(iii) Porphyromonadaceae, Lactobacillales, and Bacteroidales. Taken as a group, the taxa in 
Factor 3, including the genera Dolosigranulum, Corynebacterium, and Rothia do not differ 
significantly by LOS or ICU admission in the older age group. 
(iv) Leptotrichia, Fusobacterium, and Leptotrichiaceae.  The genera Leptrotrichia, 
Fusobacterium, and family Leptotrichiaceae comprised PCA factor 4, and are positively 
associated with the factor.  As a group, the taxa in PCA factor 4 were found to be protective and 
have a significantly decreased relative abundance in older children with longer LOS (OR=0.491: 
0.242-0.999, p=0.049).   
(v) Streptococcus, Gemella, and Prevotella.  The taxa PCA Factor 5 were also not found to 
significantly differ as a group with either ICU admission or LOS in the older age group. 
5. Relationship between SP microbiota community types, predictive features of the 
community types and pneumonia disease severity.  
A separate approach to addressing the considerable interpersonal variation in the composition of 
the lung microbiota is to use enterotypes or community types.  Community typing acts by 
clustering samples into bins based upon their taxonomic similarity, and reflect a network of co-
occurring bacterial populations (Ding, 2014).  Community types have been found to be 
associated with a wide variety of environmental and behavioral characteristics, such as diet and 
sexual activity, as well as diseases such as psoriasis and Trichomonas vaginalis (Ding, 2014).  
Even more tellingly community types at one body site have been shown to be predictive of 
community types at adjacent body sites (Ding, 2014).  We generated community types for each 
stratified population using the partitioning around the medoid approach (PAM).  This resulted in 
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three distinct community types being generated for the SP samples in the younger age group, and 
two distinct community types in the older age group (Figure 3).  In a logistic analysis, there was 
no significant association between any of the community types and disease outcomes in the 
younger age group.  However, in the older age group, community type 2 was found to be highly 
predictive of a longer LOS; though it was not possible to run the logistic model due to the 
presence of small cell values (Table 11).    
Using Random Forest plots, Moraxella, Dolosigranulum, Prevotella, Haemophilus and 
Corynebacterium are all significantly discriminant features, and taken together account for 79% 
of the total predictive value of the taxa to distinguish between community types 1 and 2 (data not 
shown).  Moraxella, Prevotella, Dolosigranulum, Corynebacterium and Haemophilus are all 
more highly enriched in Community Type 2 than 1 (Figure 4) and are thus significantly 
associated with a longer LOS.  These findings appear to be both in support and contradiction 
with some of the earlier findings; namely Corynebacterium’s presence runs counter to the LDA 
results where the taxa was associated with shorter LOS in the older age group.  Similarly, 
Prevotella’s presence in Community Type 2 is in conflict with the earlier finding from the factor 
analysis in which Prevotella positively associated with a protective Factor against longer LOS in 
the older age group (Table 9).  However, Dolosigranulum’s inclusion in Community Type 2 is 
completely consisted with the PCA results in the older age group finding a positive association 
with increased LOS.   
Discussion:  
Consistent with expectations, there were significant differences in the microbiota make-up 
between the SP samples to the NP/OP samples.  Interestingly, the NP/OP samples appeared to be 
significantly more diverse within the younger age group, though the opposite effect, though less 
  
15 
pronounced, was true for the older age group.  It is not clear why this might be the case.  Despite 
these inter-sample differences, microbial diversity did not appear to have any significant impact 
on the severity of pneumonia in either age group.  Increased diversity of the microbiota is often 
thought of as protective, as demonstrated by a recent study showing both decreased richness and 
diversity was associated with pneumonia diagnosis in CAP pediatric patients (Sakwinska, 2014).  
However, in pneumonia pathogenesis the results have been inconsistent and often inconclusive 
(Toma, 2014; Hilty, 2010; Huang, 2013).  A recent study examining high-risk vs. low-risk 
patients for clinical pulmonary infection score in hospitalized adults found no significant 
correlation between risk and the diversity of lung microbiota (Toma, 2014).   
Streptococcus was the most prevalent taxa in both samples comprising roughly 19% of the reads 
in both the NP/OP and SP samples.  This is consistent with previous findings from 16s rRNA 
data of CAP patients in both SP and NP/OP samples (Chen, 2013; Garzoni, 2013, Sakwinska, 
2014).  Genera Prevotella, Veillonella, Rothia, Neisseria, Fusobacterium, Haemophilus and 
Actinomyces have all been previously reported to be highly prevalent in the NP/OP and SP 
samples of CAP patients and were all found to rank highly here as well in relative abundance 
(Chen, 2013; Garzoni, 2013).  However, a recent Swiss study using NP/OP samples in CAP 
pediatric patients found 92% of the reads were from Moraxella, Haemophilus and Streptococcus 
alone (Sakwinska, 2014).  While Streptococcus, Moraxella, and Haemophilus are ranked first, 
fourth and ninth respectively in the NP/OP samples, and first, second and sixth in the SP 
samples, the combined relative abundance of these pathogens are only 40.87% in this study.  The 
presence of genera Prevotella Veillonella and Rothia appear to be more consistent with the 
previously mentioned studies of the U.S. young adult CAP population and may reflect a different 
etiology of pneumonia in different areas.  In contrast, Moraxella is commonly found in patients 
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with pulmonary infections across studies and is found ranking highly in both the NP/OP and SP 
samples, as well as Rothia  (Chen, 2013, Sakwinska, 2014, Garzoni, 2013).   
The results from the SP LDA and the community based analyses implicated several known CAP 
pathogens as being associated with increased pneumonia severity.  Previous studies have found 
that Moraxella, S. pneumonia and S. aureus are major causes of CAP within a younger 
population (Hashemi, 2010).  Here in this study, positive S. aureus culture was strongly 
associated with longer LOS in the fully adjusted analysis using LDA in the younger age group.  
It is not terribly surprising to find that the presence of a known CAP pathogen would be 
associated with poorer outcomes, especially given studies indicating the increased risk associated 
with co-infections of known CAP pathogens.  From the community typing, Moraxella and 
Haemophilus were more highly enriched in Community Type 2, which was strongly associated 
with a longer LOS in the older age group.  Moraxella and Haemophilus are both known CAP 
pathogens, and are known to be associated with CAP in the pediatric population (Hashemi, 2010; 
Chen, 2013; Vissing, 2013).  Previous studies have shown that Moraxella is a pnuemonia 
causing pathogen in children with CAP (Hashemi, 2010).  Moraxella is absent in the lower 
respiratory tract of healthy individuals, but recent studies have found it to be present in patients 
diagnosed with CAP (Chen, 2013).  Most of the results in this study are consistent with the idea 
that Moraxella is a CAP pathogen, including the LDA analysis in the older children finding 
Moraxella to be positively associated with ICU admission, and the Community Typing results 
again in the older children.  However, within in the younger children, PCA factor results pointed 
towards Moraxella  being a part of a factor associated with shorter LOS.  A note of caution 
should enter here that the community analyses can only infer that a factor as a whole is 
associated with a protective role, and that it may not be Moraxella driving the association seen in 
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this result, but the other taxa in the factor.  Given that lung colonization of Moraxella has been 
shown to be associated with an increased risk of pneumonia in neonates and early life children 
independent of asthma (Vissing, 2013), caution should be employed in the interpretation of this 
result.  Overall, the weight of the evidence from the various community analyses do point to 
Moraxella playing a role in CAP severity, and increased bacterial load is associated with more 
severe infection and pneumonia severity. 
Interestingly, the PCA SP analysis in the younger children indicated that the phylum 
Bacteroidetes, positively correlated with the protective PCA Factor 3, was associated with 
reduced LOS.  This phylum has previously been shown to play a protective role against 
pneumonia severity (Huang, 2013) and has previously been described as being less frequently 
found within asthmatic populations, attributed to its function of preventing against pathogenic 
invasion (Huang, 2013).  These findings suggest that Bacteroidetes may play a similar role in 
pneumonia severity, possibly by interfering with the colonization of the lung by pathogenic 
bacteria.  Similarly, previous studies have implicated Prevotella in playing a protective role 
against pathogenic invasion in pediatric patients, the presence of Prevotella was implicated as 
playing a protective role in the PCA analysis in the older age group, where it was positively 
associated with Factor 4 which was protective against longer LOS (Huang, 2013).  However, 
Prevotella was also a significantly predictive feature of Community Type 2 in the older children, 
and associated, in this analysis, with longer LOS.  Again, this result highlights the need for 
caution in interpreting the results from the community analyses and suggest that there are likely 
complex interactions at work that will require multiple different analytical approaches to 
determine their full extent. 
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Other taxa that emerged from the SP analysis include Rothia and Dolosigranulum, which here 
was found to be associated with Factor 2 in the older age group that was significantly associated 
with longer LOS, and consistently Dolosigranulum was again found to be associated with 
Community Type 2 from the community typing.  These results were consistent with previous 
studies where Rothia was identified as a possible infective agent of CAP, although it is a normal 
part of the flora in the oral cavity and upper respiratory tract (Chen, 2013).  The increased 
presence of Rothia in those with longer LOS may be an indication of a more severe pneumonia 
infection.   
Lastly, Corynebacterium was found in increased relative abundance in Community Type 2 and 
thus potentially associated with longer LOS in older kids, however this was in contrast to the 
LDA results where Corynebacterium and Actinomycs were associated with a shorter LOS in the 
younger age group.  Here, the community typing results were more consistent with previous 
findings that the phylum Actinobacteria, of which both Corynebacterium and actinomyces are a 
part, was positively associated with a CAP diagnosis as compared to a healthy population (Chen, 
2013).  Taken together, all of these finding highlight the complexity of the relationships between 
various microbes and raises the need for caution in being to quick to interpret the results from 
various microbiome analyses.  However, despite this, there was still remarkable consistency 
between many of the findings in this study and previous literature investigating the role of the 
microbiome and pneumonia etiology with the risk of developing pneumonia.   
Conclusion: 
The asthmatic pediatric population represents an at-risk population for recurrent CAP pneumonia 
(Patria, 2013).  A disturbed lung microbiota has been implicated to play a role in the onset and 
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progression of asthma (Lu, 2014; Specjalski, 2011; Hilty, 2010; Huang, 2013) as well as being 
associated with, and increasing the risk of developing pneumonia (Vissing, 2013; Sakwinska, 
2014).  Thus, it is likely that the altered status of the lung microbiota in asthmatic patients plays a 
role in the susceptibility of asthmatics to pneumonia.  This study is the first to look at significant 
predictors within the microbiome of pneumonia disease severity within the pediatric asthmatic 
population.   
Taken as a whole, this study found that many of the previously identified features of the 
microbiome known to be predictive of developing CAP or associated with the presence of CAP, 
were the same features that were predictive of poor CAP disease outcomes in the pediatric 
population, such as a longer LOS and ICU admission.  These include increased relative 
abundances of the known CAP pathogens, including Moraxella, S. pneumoniae, S. aureus and 
Haemophilus, being associated with increased odds of poorer disease outcomes, both LOS and 
ICU admission.  Similarly, Bacteroidetes’ association with shorter LOS and Rothia’s association 
with longer LOS are both consistent with previous characterizations of the bacteria in the onset 
of pneumonia and asthma (Huang, 2013; Chen, 2013). 
Corynebacterium was twice found to be associated with poor disease outcomes in the older age 
group; once in the Community Type analysis with longer LOS, and once as a part of PCA factor 
2 with longer LOS; though it appears that Corynebacterium was positively associated with the 
protective PCA factor 4 in the younger age group.  It is not clear why this disparity emerged 
between the two age groups, but previous studies have shown Corynebacterium is positively 
associated with CAP diagnosis (Chen, 2013).  Moraxella was another taxa frequently present in 
the analyses. 
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Moraxella, a known minor pneumonia causing pathogen, including in the pediatric CAP 
population (Hashemi, 2010; Chen, 2013), had a similar finding to that of Corynebacterium.  
Moraxella was associated with increased risk of ICU admission in the older age group from the 
LDA analysis, and with increased odds of longer LOS in the older age group through its 
association with Community Type 2.  However, from the PCA analysis in the younger age 
group, Moraxella was positively associated with Factor 4, which was found to be protective 
against a longer LOS.  These inconsistencies in the data analysis highlight the complex nature of 
the relationships between the different bacteria in the microbiota.  Each type of analysis has its 
own strengths and weaknesses, and seeks to highlight a different aspect of the relationship within 
the microbiome.  It is possible that some of the differences in the role of each taxa is influenced 
by the lens through which it is examined.  Prior studies have demonstrated microbiome results 
are sensitive to the methods being used, and that methods vary in their ability to detect clusters 
(Kuczynski, 2010).  Alternative explanations may be that the younger age group represents a 
different population of asthmatics than the older children, and that taxa found to be associated 
with poorer pneumonia outcomes in older children may perform a different role within the 
younger age group.   
However, simply detecting the presence of a microbe within the upper respiratory tract does not 
necessarily mean that it is the cause of the pneumonia nor that it is inhabiting the lower airways 
(Murdoch, 2012).  Previous studies have shown that SP cultures have a high sensitivity and 
specificity for pneumococcal pneumonia in adults, however it is still uncertain whether these 
specimens are of equal value for children (Murdoch, 2012).  SP samples, if collected poorly, can 
be highly contaminated with upper respiratory tract microbes, though tests exist to evaluate the 
quality of the specimens.  Similarly, some pneumonia pathogens identified from nasopharyngeal 
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tract specimens may often been associated with incidental carriage, while other, more invasive, 
serotypes have a higher positive predictive value for pneumonia etiology (Murdoch, 2012).  
However, NP/OP samples have a high negative predictive value and are of still of value in a 
clinical setting.  In our study, the microbiota present in the SP samples appeared to be 
consistently less rich and diverse than those of the NP/OP samples and were successfully 
colonized by many of the known CAP pathogens.   
Limitations  
There are several limitations to this study: (i) The data in this study was cross-sectional and taken 
after the onset of disease, and thus this study can only determine that certain taxa or groups of 
taxa are associated with poorer pneumonia outcomes in asthmatic children.  Longitudinal studies 
are needed to determine the temporal associations and infer causality.  (ii) Due to the difficulties 
surrounding asthma diagnosis in children under the age of five, it is possible that the younger age 
group likely represents a more heterogeneous population with unknown factors affecting their 
risk for pneumonia and may limit the ability to interpret the differences between the two age 
groups.  
Overall, this study demonstrates that SP samples have the potential to be used within the 
pediatric population as a non-invasive surrogate for the lung microbiome.  Though further 
studies are needed to refine and further understand the complicated relationships between the 
various taxa, and care should be used in deciding which population of children are being 
assessed.  However, this study has shown that many of the same features that are associated with 
the onset and presence of CAP may also be used to predict the progression of the disease.  
Asthma exacerbations are associated with increased health care costs among patients, and these 
exacerbations can often be caused by infections with CAP pathogens (Ivanova, 2012).  These 
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excess costs of treating an asthmatic patient with CAP result in nearly double the costs as 
compared to those patients without asthma, representing a significant opportunity for targeted 
interventions to avoid excess medical and productivity costs (Polsky, 2012). 
 
 * Numbers may not sum to total due to missing values 
+ Restricted to population to those diagnosed with asthma, radiologically confirmed pneumonia and having both np and sp samples. 
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Table 1. Age-stratified descriptive statistics for demographic characteristics, clinical 
characteristics and vaccination history, including unadjusted associations with LOS >4 days. 
 
Length of Stay  Age <5 years  Age ≥ 5 years 
 < 4 days 
N=91+ 
 
 
≥ 4 days 
N=35+ 
 
 
p-
value  
< 4 days 
N=58+ 
 
 
≥ 4 days 
N=19+ 
 
 
p-
value 
Sex 
      Female 
      Male 
 
Race 
      White 
      Black 
      Other 
 
Education* 
      <high school 
      High school/Some College 
      College and graduate 
 
Admitted From 
      Home 
      Outpatient Clinic 
      Another Hospital 
 
Co-morbidities 
      Yes 
      No 
 
Prior Antibiotics* 
      Yes 
      No 
 
Oral Steroids* 
      Yes 
      No 
 
Inhaled  Steroids* 
      Yes 
      No 
 
Vaccines:  
Seasonal Influenza * 
      Yes 
      No 
 
Pneumococcal -7 or 13 conjugate* 
      Yes 
      No 
 
H. influenza B * 
      Yes 
      No 
    
 39    (42.9) 
 52    (57.1) 
 
 
  7      (7.7)      
80    (87.9) 
  4      (4.4) 
 
 
  8      (9.0)    
72    (80.9) 
  9    (10.1) 
 
 
74    (82.2) 
  6      (6.7) 
10    (11.1) 
 
 
18    (19.8) 
73    (80.2) 
 
 
25    (27.5) 
66    (72.5) 
 
 
13    (14.4) 
77    (85.6) 
 
 
19    (24.1) 
60    (76.0) 
 
 
 
21    (24.1) 
66    (75.9)   
   
89    (98.9) 
  1      (1.1) 
 
 
87    (96.7) 
  3      (3.3) 
  
 17    (48.6) 
 18    (51.4) 
 
 
  4      (9.4) 
24    (68.6) 
  7    (20.0) 
 
 
  5    (14.3) 
26    (74.3) 
  4    (11.4) 
 
 
30    (85.7) 
  3      (8.6) 
  2      (5.7) 
 
 
12    (34.3) 
23    (65.7) 
 
 
  8    (22.9) 
27    (77.1) 
 
 
  7    (20.6) 
27    (79.4) 
 
 
  6    (19.4) 
25    (80.7) 
 
 
 
12    (34.3) 
23    (65.7) 
  
   
35  (100.0) 
  0      (0.0) 
 
 
34    (97.1) 
  1      (2.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.563 
 
 
 
0.014 
 
 
 
 
0.653 
 
 
 
 
0.629 
 
 
 
 
0.087 
 
 
 
0.598 
 
 
 
0.407 
 
 
 
0.597 
 
 
 
 
0.254 
 
 
 
0.720 
 
 
 
1.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 23    (39.7) 
 35    (60.3) 
 
 
  7    (12.1) 
49    (84.5) 
  2      (3.5) 
 
 
  6    (10.7) 
35    (62.5) 
15    (26.8) 
 
 
41    (71.9) 
  5      (8.8) 
11    (19.3) 
 
 
  6    (10.3) 
52    (89.7) 
 
 
  8    (13.8) 
50    (86.2) 
 
 
  7    (12.1) 
51    (87.9) 
 
 
27    (50.9) 
26    (49.1) 
 
 
 
11    (19.3) 
46    (80.7)   
 
52    (89.7) 
  6    (10.3) 
 
 
57    (98.3) 
  1      (1.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 10    (52.6) 
   9    (47.4) 
 
 
  0      (0.0)    
19  (100.0) 
  0      (0.0) 
 
 
  0      (0.0)    
14    (73.7) 
  5    (26.3) 
 
 
13    (68.4) 
  3    (15.8) 
  3    (15.8) 
 
 
  5    (26.3) 
14    (73.7) 
 
 
  4    (21.1) 
15    (79.0) 
 
 
  5    (26.3) 
14    (73.7) 
 
 
10    (52.6) 
  9    (47.4) 
 
 
 
  3    (15.8) 
16    (84.2)   
 
11    (57.9) 
  8    (42.4) 
 
 
18    (94.7) 
  1      (5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.321 
 
 
 
0.188 
 
 
 
 
0.315 
 
 
 
 
0.675 
 
 
 
 
0.127 
 
 
 
0.476 
 
 
 
0.157 
 
 
 
0.900 
 
 
 
 
0.956 
 
 
 
0.004 
 
 
 
0.435 
 
 * Numbers may not sum to total due to missing values 
+ Restricted to population to those diagnosed with asthma, radiologically confirmed pneumonia and having both np and sp samples. 
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Table 2. Descriptive statistics for demographic characteristics, clinical characteristics and 
vaccination history, including unadjusted associations for ICU admission in the older age group.  
ICU Admission 
Age ≥ 5 years 
 
 
Not Admitted 
n = 68+  
Admitted 
n = 9+ 
 
p-value 
Sex 
      Female 
      Male 
 
Race 
      White 
      Black 
      Other 
 
Education* 
      <high school 
      High school/Some College 
      College and graduate 
 
Admitted From 
      Home 
      Outpatient Clinic 
      Another Hospital 
 
Co-morbidities 
      Yes 
      No 
 
Prior Antibiotics* 
      Yes 
      No 
 
Oral Steroids* 
      Yes 
      No 
 
Inhaled  Steroids* 
      Yes 
      No 
 
Vaccines:  
Seasonal Influenza * 
      Yes 
      No 
 
Pneumococcal -7 or 13 conjugate * 
      Yes 
      No 
 
H. influenza B * 
      Yes 
      No 
  
  28   (41.2) 
  40   (58.8) 
 
 
   7   (10.3) 
 59   (86.8) 
   2     (2.9) 
 
 
   5     (7.6) 
 41   (62.1) 
 20   (30.3) 
 
 
 47   (70.2) 
   7   (10.5) 
 13   (19.4) 
 
 
    9   (13.2) 
  59   (86.8) 
 
 
  11   (16.2) 
  57   (83.8) 
 
 
  10   (14.7) 
  58   (85.3) 
 
 
  30   (47.6) 
  33   (52.4) 
 
 
 
  10   (14.9) 
  57   (85.1)   
 
  56   (82.4) 
  12   (17.7) 
 
 
  67   (98.5) 
    1     (1.5) 
  
 
 
    5   (55.6) 
    4   (44.4) 
 
 
   0     (0.0) 
   9 (100.0) 
   0     (0.0) 
 
 
   1   (11.1) 
   8   (88.9) 
   0     (0.0) 
 
 
   7   (77.8) 
   1   (11.1) 
   1   (11.1) 
 
 
    2   (22.2) 
    7   (77.8) 
 
 
    1   (11.1) 
    8   (88.9) 
 
 
    2   (22.2) 
    7   (77.8) 
 
 
    7   (77.8) 
    2   (22.2) 
 
 
 
    4   (44.4) 
    5   (55.6)   
 
    7   (77.8) 
    2   (22.2) 
 
 
    8   (88.9) 
    1   (11.1) 
    
 
  0.413 
 
 
 
0.509 
 
 
 
 
0.156 
 
 
 
 
0.833 
 
 
 
 
0.469 
 
 
 
0.694 
 
 
 
0.559 
 
 
 
0.090 
 
 
 
 
0.032 
 
 
 
0.738 
 
 
   
0.088 
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Table 3.  Age-stratified unadjusted associations with LOS >4 days for CAP bacterial sputum 
cultures.   
 Length of Stay 
Age <5 years  Age ≥ 5 years   
 < 4 days 
N=91 
 ≥ 4 days 
N=35 
 
 
p-
value  
< 4 days 
N= 58 
 ≥ 4 days 
N=19 
 
 
p-
value 
S. pneumoniae 
      Yes 
      No 
 
S. aureus 
      Yes 
      No 
 
M. catarrhalis 
      Yes 
      No 
 
H. Influenzae 
      Yes 
      No 
 
  
 
 
18   (19.8) 
73   (80.2) 
 
 
10   (11.0) 
81   (89.0)       
 
20   (22.0) 
71   (78.0)       
 
12   (13.2) 
79   (86.8) 
  
  9   (25.7) 
26   (74.3) 
 
 
13   (37.1) 
22   (62.9)       
 
  9   (25.7) 
26   (74.3)       
 
  8   (22.9) 
27   (77.1) 
 0.467 
 
 
 
<0.001 
 
 
 
0.655 
 
 
 
0.183 
 
 
  
 3      (5.2) 
55   (94.8) 
 
 
12   (20.7) 
46   (79.3)       
 
  2     (3.5) 
56   (96.6)       
 
  3     (5.2) 
55   (94.8) 
  
  0     (0.0) 
19 (100.0) 
 
 
  3   (15.8) 
16   (84.2)       
 
  0     (0.0) 
19 (100.0)       
 
  2   (10.5) 
17   (89.5) 
 0.571 
 
 
 
0.750 
 
 
 
1.000 
 
 
 
0.592 
 
 
 
 
 
Table 4.  Unadjusted associations with ICU admission for CAP bacterial sputum cultures within 
the older age group. 
 ICU Admission 
Age ≥ 5 years   
Not Admitted 
n = 68 
 
 
Admitted 
n = 9 
 
p-value 
S. pneumoniae 
      Yes 
      No 
 
S. aureus 
      Yes 
      No 
 
M. catarrhalis 
      Yes 
      No 
 
H. Influenzae 
      Yes 
      No 
 
 
 
 
     3    (4.4) 
   65  (95.6) 
 
 
   14   (20.6) 
   54   (79.4)       
 
     2     (2.9) 
   66   (97.1)       
 
     5     (7.4) 
   63   (92.7) 
 
 
 
 
 
 
 
 
 
     0     (0.0) 
     9 (100.0) 
 
 
     1   (11.1) 
     8   (88.9)       
 
     0     (0.0) 
     9 (100.0)       
 
     0     (0.0) 
     9 (100.0) 
 
 
0.520 
 
 
 
0.246 
 
 
 
0.602 
 
 
 
0.400 
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Table 5. Age-stratified, unadjusted associations with LOS for the bacterial cultures of sputum 
samples and viral PCR results on nasopharyngeal/oropharyngeal samples. 
 Length of Stay  
Age <5 years   Age ≥ 5 years   
 
 
< 4 days 
N=91 
 
 
≥ 4 days 
N=35 
 p-
value 
 < 4 days 
N= 58 
 ≥ 4 days 
N=19 
 
 
p-
value 
Mycoplasma 
      Yes 
      No 
 
Viruses: 
Rhinovirus 
      Combined 
      Alone 
      None 
 
RSV 
      Yes 
      No 
 
Adenovirus 
      Yes 
      No 
 
Coronavirus 
      Yes 
      No 
 
Parainfluenzae 
      Yes 
      No 
 
Metapneumovirus 
      Yes 
      No 
 
  
  2     (2.2) 
89   (97.8) 
 
 
 
24   (26.4) 
18   (19.8) 
49   (53.9) 
 
 
38   (41.8) 
53   (58.2) 
 
 
23   (25.3) 
68   (74.7) 
 
 
10   (11.0) 
81   (89.0) 
 
 
  5     (5.5) 
86   (94.5) 
 
 
  4     (4.4) 
87   (95.6) 
  
  0     (0.0) 
35 (100.0) 
 
 
 
   7   (20.0) 
   3     (8.6) 
 25   (71.4) 
 
 
15   (42.9) 
20   (57.1) 
 
 
  6   (17.1) 
29   (82.9) 
 
 
  3     (8.6) 
32   (91.4) 
 
 
  1     (2.9) 
34   (97.1) 
 
 
  3     (8.6) 
32   (91.4) 
 1.000 
 
 
 
 
0.161 
 
 
 
 
0.911 
 
 
 
0.331 
 
 
 
0.987 
 
 
 
0.865 
 
 
 
 
0.396 
  
  5     (8.6) 
53   (91.4) 
 
 
 
10   (17.2) 
27   (46.6) 
21   (36.2) 
 
 
  6   (10.3) 
52   (89.7) 
 
 
  3     (5.2) 
55   (94.8) 
 
 
  2     (3.5) 
56   (96.6) 
 
 
  4     (6.9) 
54   (93.1) 
 
 
  1     (1.7) 
57   (98.3) 
  
 0      (0.0) 
19 (100.0) 
 
 
 
   2   (10.5) 
   7   (36.8) 
 10   (52.6) 
 
 
  1     (5.3) 
18   (94.7) 
 
 
  1     (5.3) 
18   (94.7) 
 
 
  1     (5.3) 
18   (94.7) 
 
 
  0     (0.0) 
19 (100.0) 
 
 
  0     (0.0) 
19 (100.0) 
 0.325 
 
 
 
 
0.432 
 
 
 
 
0.674 
 
 
 
1.000 
 
 
 
0.988 
 
 
 
0.567 
 
 
 
1.000 
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Table 6. Unadjusted associations with ICU admission for the bacterial cultures of sputum 
samples and viral PCR results on nasopharyngeal/oropharyngeal samples. 
 ICU Admission 
 Age ≥ 5 years 
  Not Admitted 
n = 68 
 
 
Admitted 
n = 9 
 p-
value 
Mycoplasma 
      Yes 
      No 
 
Viruses: 
Rhinovirus 
      Combined 
      Alone 
      None 
 
RSV 
      Yes 
      No 
 
Adenovirus 
      Yes 
      No 
 
Coronavirus 
      Yes 
      No 
 
Parainfluenzae 
      Yes 
      No 
 
Metapneumovirus 
      Yes 
      No 
 
       
     5     (7.4) 
   63   (92.7) 
 
 
 
   10   (14.7) 
   30   (44.1) 
   28   (41.2) 
 
 
     7   (10.3) 
   61   (89.7) 
 
 
     3     (4.4) 
   65   (95.6) 
 
 
     2     (2.9) 
   66   (97.1) 
 
 
     3     (4.4) 
   65   (95.6) 
 
 
     1     (1.5) 
   67   (98.5) 
 
 
 
     0     (0.0) 
     9 (100.0) 
 
 
 
      2   (22.2) 
      4   (44.4) 
      3   (33.3) 
 
 
     0     (0.0) 
     9 (100.0) 
 
 
     1   (11.1) 
     8   (88.9) 
 
 
     1   (11.1) 
     8   (88.9) 
 
 
     1   (11.1) 
     8   (88.9) 
 
 
     0     (0.0) 
     9 (100.0) 
 0.400 
 
 
 
 
0.815 
 
 
 
 
0.313 
 
 
 
0.395 
 
 
 
0.234 
 
 
 
0.395 
 
 
 
0.714 
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Table 7.  Relationship between evenness and Shannon diversity indices and the 
nasopharyngeal/oropharyngeal (NP/OP) and sputum (SP) samples in the age-stratified 
population.  T-tests were performed on the mean difference between the diversity indices in the 
SPand NP/OP samples and presented with standard deviation (std) and p-values. 
Age Stratification 
Total: 
Mean Difference    
(SP-NP/OP: ± std) 
0 - < 5 years: 
Mean Difference    
(SP-NP/OP: ± std) 
 ≤ 5 to <18 years: 
Mean Difference    
(SP-NP/OP: ± std) 
 
n = 203  p-value 
 
n = 126  p-value  n = 77  p-value 
Eveness 
 -0.022     
± 0.141  
0.031 
 
-0.056 
± 0.140 
 
<0.001 
 
0.035 
± 0.126 
 
0.018 
Shannon Index 
 
-0.272     
± 0.993 
 <0.001  -0.530   
± 1.022 
 <0.001  0.150 
± 0.782 
 0.097 
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Table 8.  Top 26 mean-ranked taxa within the nasopharyngeal/oropharyngeal (NP/OP) samples 
and the sputum (SP) samples based upon the 16s rRNA data for the population as a whole.  The 
cutoff for inclusion was 0.6 mean-relative abundance in either the SP or the NP/OP samples. 
 
Sputum Samples Nasopharyngeal Samples 
Ranking 
Taxa  Mean (%)  
STD 
(%)  Taxa  
Mean 
(%)  
STD 
(%) 
1  
 
Streptococcus  24.11  18.8
9 
 Streptococcus  32.68  19.2
0 2 Moraxella  12.22  22.
2 
 Prevotella  10.91  10.6
3 3  Prevotella  10.23  12.6
1 
 Veillonella  7.74  6.08
4  Pasteurellaceaeb  7.78  12.6
3 
 Moraxella  5.89  13.2
5 5  Haemophilus  6.67  14.1
0 
 Rothia  5.18  6.03
6  Veillonella  4.75  5.21  Pasteurellaceaeb  2.76  5.25 
7  Neisseria  3.95  6.81  Neisseria  2.41  4.76 
8  Fusobacterium  3.14  3.83  Actinomyces  2.40  2.48 
9  Porphyromonadace
aeb 
 2.14  3.16  Haemophilus  2.30  6.42 
10  Rothia  1.98  3.21  Lactobacillalesd  2.08  2.74 
11  Bacteroidetesa  1.96  3.13  Dolosigranulum  2.05  4.97 
12  Actinomyces  1.48  2.41  Corynebacterium  2.02  6.05 
13  Bacteroidalesd  1.44  1.97  Gemella  1.75  3.04 
14  Leptotrichia  1.33  1.87  Fusobacterium  1.55  2.23 
15  Gemella  1.28  1.81  Porphyromonadaceaeb  1.54  2.94 
16  Lactobacillalesd  1.00  1.94  Bacteroidalesd  1.30  1.91 
17  Capnocytophaga  0.96  2.33  Leptotrichia  0.97  1.75 
18  Leptotrichiaceaeb  0.91  1.57  Bacteroidetesa  0.93  2.04 
19  Betaproteobacteriac  0.85  2.30  Atopobium  0.92  1.40 
20  Veillonellaceaeb  0.72  1.24  Actinomycetaceaeb  0.92  1.51 
21  Mycoplasma  0.69  5.08  Leptotrichiaceaeb  0.70  1.52 
22  Corynebacterium  0.68  1.65  Capnocytophaga  0.69  2.60 
23  Dolosigranulum  0.60  1.83  Veillonellaceaeb  0.52  0.67 
24  Actinomycetaceaeb  0.32  0.74  Betaproteobacteriac  0.34  1.14 
25  Atopobium  0.28  0.62  Lactobacillus  0.10  0.69 
26  Lactobacillus  0.07  0.53  Mycoplasma  0.02  0.06 
aPhylum 
bFamily 
cClass 
dSuborder 
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a.         
b.                 
Figure 1. Linear discriminant analysis (LDA) showing taxa significantly enriched in the sputum 
samples (red) and the nasopharyngeal/oropharyngeal samples (green).  a. LDA results in the 
younger age group. b. LDA results in the older age group. 
 
 
  
31 
 
a.          
b.  
Figure 2. Results from the Linear Discriminant Analysis performed on the sputum samples 
showing significantly enriched taxa in patients with LOS <4 days (red).  a. LDA sputum results 
in the younger age group. b. LDA sputum results in the older age group. 
1 Family 
 
1 
1 
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Table 9.  PCA Factors for the sputum samples in the younger age group.  1 Factor significantly 
associated with shorter LOS in younger age group, p<0.05.  2 Category combining rare and 
unclassified bacteria.   
Sputum, <5 years   Factor 1  Factor 2  Factor 3 1  Factor 4 1 
Atopobium  88       
Veillonella  83       
Actinomycetaceaeb  83       
Actinomyces  81       
Leptotrichia    64     
Capnocytophaga    63     
Neisseria    54     
Other rare taxa2    53     
Lactobacillalesd    49     
Betaproteobacteriac    48     
Moraxella    -41    41 
Veillonellaceaeb      83   
Bacteroidetesa      80   
Mycoplasma      55   
Leptotrichiaceaeb      50  -43 
Fusobacterium        -50 
Bacteroidalesd        -40 
Corynebacterium        74 
Dolosigranulum        75 
aPhylum 
bFamily 
cClass 
dSuborder 
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Table 10.  PCA Factors for the sputum samples in the older age group.  1, 2 Factor significantly 
associated with shorter and longer LOS in older age group, respectively (p<0.05).    3 No factors 
were significantly associated with ICU admission in older age group. 
Sputum, ≥ 5 years  Factor 1  Factor 2 1  Factor 3  Factor 4 2  Factor 5 
Veillonella  79         
Atopobium  71         
Actinomyces  55         
Prevotella  51        -58 
Pasteurellaceaeb  -50         
Neisseria  -56         
Dolosigranulum    86       
Corynebacterium    75       
Rothia    72       
Porphyromonadaceaeb      84     
Lactobacillalesd      81     
Bacteroidalesd      55     
Leptotrichia        74   
Fusobacterium        71   
Leptotrichiaceaeb        64   
Streptococcus          87 
Gemella          62 
bFamily 
dSuborder 
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a.  b.  
Figure 3. Principal Coordinate Analysis generating the community types from the clustering of 
sputum samples. a. Three distinct community types from clustering within the younger age 
group. b. Two distinct community types from clustering within the older age group. 
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Figure 4. Heat map of the makeup of the two sputum community types within the older pediatric 
study population.  The heat map represents the proportion of subjects within each community 
type within the top quartile of each taxa’s relative abundances.   
(_P) = Phylum 
(_F) = Family 
(_C) = Class 
(_O) = Suborder 
 
 
Table 11.  Contingency table for LOS outcome by sputum sample Community Type in the older 
age group. 
LOS  Sputum ≥ 5 years: 
Community Type 
 
≥ 4 days  < 4 days  
Total 
1  5  52  57 
2  19  1  20 
   Community Type:        1                                         2 
 
  
 
 
  
2 
Sputum Community Type Make-up in 
≥5 Age Group 
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